| Intermediate 111 pts. | 31 pts. with second-HIFU | |||||||
| Variables | No. pts. | 5y-RFS rate (%) | P-value | No. pts. | 5y-RFS rate (%) | P-value | ||
| T-stage | T1 | 57 | 87 | 0.022 | 15 | 63 | 0.766 | |
| T2 | 54 | 68 | 16 | 65 | ||||
| Gleason score | ≤3 + 4 | 88 | 81 | 0.314 | ≤6 | 9 | 100 | 0.228 |
| ≥4 + 3 | 23 | 66 | 7 | 14 | 63 | |||
| ≥8 | 8 | 29 | ||||||
| Pretreatment PSA | <10 | 67 | 85 | 0.066 | 19 | 58 | 0.314 | |
| (ng/mL) | ≥10 | 44 | 68 | 12 | 79 | |||
| Nadir PSA | <0.1 | 55 | 90 | 0.002 | 9 | 100 | 0.018 | |
| (ng/mL) | ≥0.1 | 56 | 64 | 22 | 48 | |||
| ADT before HIFU | --- | 88 | 78 | 0.219 | ||||
| ≥3 M | 23 | 77 | ||||||
| HIFU device | Sonablate 500 | 27 | 77 | 0.139 | 12 | 58 | 0.751 | |
| Version 4 | 84 | 78 | 19 | 64 | ||||